Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Study of DS-3939a in Subjects With Advanced Solid Tumors
2023-507937-14-00Phase 2Authorised
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of DS-3939 in advanced nonhematological malignancy, Metastatic solid neoplasm and prostate cancer (PCa), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Dose-limiting toxicities (DLTs), Treatment-emergent adverse events (TEAEs) and 3 more. Planned start Oct 2024; status: authorised.
02
Drugs
DS-3939
03
Conditions
advanced nonhematological malignancyMetastatic solid neoplasmprostate cancer (PCa)
Beyond the preview
Go deeper on 2023-507937-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507937-14-00.